• Consensus Rating: Buy
  • Consensus Price Target: $101.19
  • Forecasted Upside: -5.01%
  • Number of Analysts: 16
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 16 Buy Ratings
  • 0 Strong Buy Ratings
▲ +1.01 (0.96%)

This chart shows the closing price for NTRA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Natera Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NTRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NTRA

Analyst Price Target is $101.19
▼ -5.01% Downside Potential
This price target is based on 16 analysts offering 12 month price targets for Natera in the last 3 months. The average price target is $101.19, with a high forecast of $142.00 and a low forecast of $68.00. The average price target represents a -5.01% upside from the last price of $106.52.

This chart shows the closing price for NTRA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 16 contributing investment analysts is to buy stock in Natera. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 16 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 16 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 16 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 16 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 16 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 16 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 16 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 16 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 16 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/3/2024Jefferies Financial GroupInitiated CoverageBuy$142.00Low
5/14/2024Piper SandlerBoost TargetOverweight ➝ Overweight$110.00 ➝ $120.00Low
5/13/2024BTIG ResearchBoost TargetBuy ➝ Buy$100.00 ➝ $125.00Low
5/10/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$100.00 ➝ $130.00Low
5/10/2024TD CowenBoost TargetBuy ➝ Buy$123.00 ➝ $137.00Low
5/10/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$99.00 ➝ $117.00Low
4/15/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$90.00 ➝ $100.00Low
4/8/2024Craig HallumInitiated CoverageBuy$117.00Low
4/5/2024Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$120.00Low
3/6/2024Piper SandlerBoost TargetOverweight ➝ Overweight$70.00 ➝ $110.00Low
2/29/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$80.00 ➝ $90.00Low
2/29/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$87.00 ➝ $100.00Low
2/20/2024Raymond JamesDowngradeStrong-Buy ➝ Outperform$68.00 ➝ $85.00Low
1/30/2024StephensReiterated RatingOverweight ➝ Overweight$78.00Low
1/29/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$64.00 ➝ $80.00Low
1/17/2024StephensReiterated RatingOverweight ➝ Overweight$78.00Low
12/29/2023The Goldman Sachs GroupBoost TargetBuy ➝ Buy$56.00 ➝ $64.00Low
12/29/2023BTIG ResearchBoost TargetBuy ➝ Buy$75.00 ➝ $85.00Low
12/14/2023GuggenheimInitiated CoverageBuy$70.00Low
12/13/2023Wolfe ResearchInitiated CoverageOutperform$70.00Low
12/12/2023TD CowenBoost TargetOutperform ➝ Outperform$82.00 ➝ $87.00Low
11/13/2023Raymond JamesUpgradeOutperform ➝ Strong-Buy$68.00Low
11/10/2023Morgan StanleyLower TargetOverweight ➝ Overweight$70.00 ➝ $68.00Low
11/9/2023UBS GroupLower TargetBuy ➝ Buy$76.00 ➝ $70.00Low
10/20/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$60.00 ➝ $52.00Low
10/16/2023Piper SandlerLower TargetOverweight ➝ Overweight$80.00 ➝ $70.00Low
9/28/2023Sanford C. BernsteinInitiated CoverageMarket Perform$48.00Low
8/8/2023Piper SandlerBoost TargetOverweight ➝ Overweight$70.00 ➝ $80.00Low
8/7/2023Morgan StanleyLower TargetOverweight ➝ Overweight$72.00 ➝ $70.00Low
8/4/2023Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$70.00Low
7/21/2023The Goldman Sachs GroupLower TargetBuy$70.00 ➝ $60.00Low
5/30/2023Piper SandlerLower Target$80.00 ➝ $70.00Low
5/10/2023Robert W. BairdBoost Target$65.00 ➝ $66.00Low
5/10/2023Credit Suisse GroupBoost Target$65.00 ➝ $70.00Low
5/5/2023UBS GroupInitiated CoverageBuy$76.00Low
3/3/2023Raymond JamesBoost TargetOutperform$58.00 ➝ $68.00Low
3/2/2023Morgan StanleyBoost TargetOverweight$70.00 ➝ $72.00Low
3/1/2023Credit Suisse GroupBoost TargetOutperform$55.00 ➝ $65.00Low
2/17/2023Piper SandlerBoost Target$70.00 ➝ $80.00Low
1/18/2023Raymond JamesUpgradeMarket Perform ➝ Outperform$58.00Low
1/17/2023Piper SandlerReiterated RatingOverweight$70.00Low
11/16/2022StephensLower Target$67.00Low
11/14/2022Credit Suisse GroupLower TargetOutperform$70.00 ➝ $55.00Low
11/9/2022BTIG ResearchLower Target$95.00 ➝ $75.00Low
11/9/2022Robert W. BairdLower Target$72.00 ➝ $65.00Low
8/24/2022Credit Suisse GroupInitiated CoverageOutperform$70.00Low
8/17/2022Piper SandlerBoost TargetOverweight$60.00 ➝ $70.00Low
8/15/2022BTIG ResearchBoost Target$95.00N/A
8/5/2022JPMorgan Chase & Co.Boost Target$80.00 ➝ $100.00Low
5/15/2022Piper SandlerLower TargetNA$75.00 ➝ $60.00Low
5/6/2022CowenLower Target$110.00 ➝ $100.00High
5/6/2022CowenLower Target$110.00 ➝ $100.00High
5/6/2022Robert W. BairdLower Target$100.00 ➝ $71.00High
4/25/2022StephensInitiated CoverageOverweight$54.00High
4/19/2022The Goldman Sachs GroupLower TargetBuy$90.00 ➝ $80.00High
4/13/2022Piper SandlerBoost TargetOverweight ➝ Overweight$70.00 ➝ $75.00Medium
3/21/2022Piper SandlerLower TargetOverweight$80.00 ➝ $70.00Medium
3/10/2022BTIG ResearchLower Target$125.00 ➝ $100.00High
3/8/2022The Goldman Sachs GroupInitiated CoverageBuy$90.00High
3/1/2022Piper SandlerLower Target$110.00 ➝ $80.00Medium
2/28/2022Morgan StanleyLower TargetOverweight$118.00 ➝ $110.00Medium
2/25/2022Robert W. BairdLower TargetOutperform$152.00 ➝ $100.00High
2/17/2022CowenLower Target$150.00 ➝ $110.00High
2/15/2022Morgan StanleyLower TargetOverweight$148.00 ➝ $118.00Medium
1/24/2022Wells Fargo & CompanyLower Target$135.00 ➝ $100.00High
1/12/2022BTIG ResearchLower Target$150.00High
1/6/2022Piper SandlerInitiated CoverageOverweight$110.00Low
11/5/2021Robert W. BairdBoost TargetOutperform$145.00 ➝ $152.00High
10/15/2021CowenInitiated CoverageOutperform$150.00Low
8/9/2021Piper SandlerBoost TargetOverweight$155.00 ➝ $160.00Medium
8/6/2021Wells Fargo & CompanyBoost TargetOverweight$125.00 ➝ $135.00High
8/6/2021Robert W. BairdBoost TargetOutperform$127.00 ➝ $145.00High
8/6/2021BTIG ResearchBoost TargetBuy$155.00 ➝ $160.00High
7/20/2021Craig HallumBoost TargetBuy$134.00 ➝ $139.00Low
7/6/2021Piper SandlerBoost TargetOverweight$150.00 ➝ $155.00Low
6/23/2021BTIG ResearchBoost TargetBuy$150.00 ➝ $155.00Medium
6/21/2021Wells Fargo & CompanyBoost TargetOverweight$110.00 ➝ $125.00High
6/21/2021SVB LeerinkBoost TargetPositive ➝ Outperform$140.00 ➝ $160.00High
6/15/2021Raymond JamesInitiated CoverageMarket PerformMedium
5/25/2021Truist FinancialLower TargetBuy$143.00 ➝ $129.00High
5/25/2021Wells Fargo & CompanyInitiated CoverageOverweight$110.00High
5/10/2021Morgan StanleyLower TargetOverweight$140.00 ➝ $135.00High
5/7/2021BTIG ResearchBoost TargetBuy$145.00 ➝ $150.00Medium
3/1/2021Morgan StanleyBoost TargetOverweight$87.00 ➝ $140.00Low
2/26/2021Piper SandlerBoost TargetTop Pick ➝ Overweight$127.00 ➝ $150.00Medium
1/27/2021Truist FinancialInitiated CoverageBuy$143.00High
1/20/2021SVB LeerinkBoost TargetOutperform$95.00 ➝ $140.00Low
1/19/2021BTIG ResearchBoost TargetBuy$112.00 ➝ $135.00Medium
1/4/2021Craig HallumBoost TargetBuy$92.00 ➝ $118.00N/A
12/16/2020Piper SandlerBoost TargetPositive ➝ Overweight$92.00 ➝ $127.00High
12/2/2020BTIG ResearchBoost TargetAverage ➝ Buy$95.00 ➝ $105.00Medium
11/13/2020SVB LeerinkBoost TargetOutperform$84.00 ➝ $95.00Low
11/6/2020JPMorgan Chase & Co.Boost TargetOverweight$75.00 ➝ $90.00High
11/6/2020Morgan StanleyBoost TargetAverage ➝ Overweight$80.00 ➝ $87.00High
11/6/2020Piper SandlerBoost TargetOverweight$76.00 ➝ $92.00High
11/6/2020SVB LeerinkBoost TargetOutperform$75.00 ➝ $84.00High
10/7/2020BTIG ResearchInitiated CoverageBuy$90.00Medium
9/28/2020Morgan StanleyInitiated CoverageOverweight$80.00Medium
9/24/2020Craig HallumBoost TargetBuy$66.00 ➝ $82.00High
9/17/2020SVB LeerinkInitiated CoverageOutperform$75.00Low
8/6/2020Robert W. BairdBoost TargetOutperform$42.00 ➝ $60.00High
8/6/2020JPMorgan Chase & Co.Boost TargetOverweight$45.00 ➝ $60.00High
6/22/2020Piper SandlerReiterated RatingBuy$63.00Low
5/21/2020CfraLower TargetBuy ➝ Hold$39.00 ➝ $36.00Low
5/14/2020Piper SandlerBoost TargetOverweight$49.00 ➝ $56.00Medium
5/7/2020Robert W. BairdBoost TargetOutperform$40.00 ➝ $42.00High
5/7/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$32.00 ➝ $45.00High
4/15/2020CowenBoost TargetOutperform$32.00 ➝ $40.00Medium
2/27/2020Piper SandlerBoost TargetOverweight$45.00 ➝ $49.00High
12/19/2019Craig HallumReiterated RatingBuy$49.00High
11/7/2019Craig HallumBoost TargetBuy$37.00 ➝ $49.00High
11/4/2019JPMorgan Chase & Co.Boost TargetNeutral$27.00 ➝ $32.00High
10/18/2019CowenBoost TargetOutperform ➝ Average$30.00 ➝ $42.00Low
10/11/2019Piper Sandler CompaniesSet TargetBuy$45.00Low
9/24/2019Piper Sandler CompaniesBoost TargetOverweight$32.00 ➝ $45.00Low
8/22/2019Piper Sandler CompaniesReiterated RatingBuyLow
8/8/2019Craig HallumBoost TargetBuy$29.00 ➝ $37.00High
8/8/2019Piper Sandler CompaniesBoost TargetOverweight$28.00 ➝ $32.00High
(Data available from 7/23/2019 forward)

News Sentiment Rating

1.27 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 12 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
  • 16 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 14 very positive mentions
  • 19 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
  • 22 very positive mentions
  • 22 positive mentions
  • 1 negative mentions
  • 4 very negative mentions
  • 21 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 23 very positive mentions
  • 22 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 23 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 19 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 19 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Natera logo
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.
Read More

Today's Range

Now: $106.52
Low: $105.41
High: $109.18

50 Day Range

MA: $109.27
Low: $101.15
High: $114.44

52 Week Range

Now: $106.52
Low: $36.90
High: $117.23


895,366 shs

Average Volume

1,329,804 shs

Market Capitalization

$13.08 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Natera?

The following Wall Street research analysts have issued stock ratings on Natera in the last year: BTIG Research, Canaccord Genuity Group Inc., Craig Hallum, Credit Suisse Group AG, Guggenheim, Jefferies Financial Group Inc., Morgan Stanley, Piper Sandler, Raymond James, Robert W. Baird, Sanford C. Bernstein, Stephens, StockNews.com, TD Cowen, The Goldman Sachs Group, Inc., UBS Group AG, and Wolfe Research.
View the latest analyst ratings for NTRA.

What is the current price target for Natera?

16 Wall Street analysts have set twelve-month price targets for Natera in the last year. Their average twelve-month price target is $101.19, suggesting a possible downside of 4.0%. Jefferies Financial Group Inc. has the highest price target set, predicting NTRA will reach $142.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $68.00 for Natera in the next year.
View the latest price targets for NTRA.

What is the current consensus analyst rating for Natera?

Natera currently has 16 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NTRA will outperform the market and that investors should add to their positions of Natera.
View the latest ratings for NTRA.

What other companies compete with Natera?

How do I contact Natera's investor relations team?

Natera's physical mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company's listed phone number is (650) 249-9090 and its investor relations email address is [email protected]. The official website for Natera is www.natera.com. Learn More about contacing Natera investor relations.